MX2023013912A - Metodos para inhibir ras. - Google Patents

Metodos para inhibir ras.

Info

Publication number
MX2023013912A
MX2023013912A MX2023013912A MX2023013912A MX2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A
Authority
MX
Mexico
Prior art keywords
methods
inhibiting ras
inhibiting
ras
disclosure
Prior art date
Application number
MX2023013912A
Other languages
English (en)
Spanish (es)
Inventor
Kyle Seamon
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2023013912A publication Critical patent/MX2023013912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2023013912A 2021-05-25 2022-05-25 Metodos para inhibir ras. MX2023013912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192837P 2021-05-25 2021-05-25
PCT/US2022/030823 WO2022251292A1 (en) 2021-05-25 2022-05-25 Methods for inhibiting ras

Publications (1)

Publication Number Publication Date
MX2023013912A true MX2023013912A (es) 2024-02-12

Family

ID=82115695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013912A MX2023013912A (es) 2021-05-25 2022-05-25 Metodos para inhibir ras.

Country Status (11)

Country Link
US (1) US20240277796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346898A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521774A (cg-RX-API-DMAC7.html)
KR (1) KR20240026526A (cg-RX-API-DMAC7.html)
CN (2) CN117715658A (cg-RX-API-DMAC7.html)
AU (1) AU2022281343A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219533A1 (cg-RX-API-DMAC7.html)
IL (1) IL308771A (cg-RX-API-DMAC7.html)
MX (1) MX2023013912A (cg-RX-API-DMAC7.html)
TW (1) TW202313631A (cg-RX-API-DMAC7.html)
WO (1) WO2022251292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4463231A1 (en) * 2022-01-10 2024-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2023232776A1 (en) * 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
PE20252395A1 (es) 2023-02-14 2025-10-10 Hoffmann La Roche Compuestos triciclicos para el tratamiento de cancer
CN121487738A (zh) * 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
TW202446387A (zh) * 2023-04-06 2024-12-01 瑞士商赫孚孟拉羅股份公司 用於治療癌症之三環化合物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121693329A (zh) * 2023-07-14 2026-03-17 锐新医药公司 治疗ras相关疾病或病症的方法
WO2025162395A1 (zh) * 2024-02-01 2025-08-07 山东先声生物制药有限公司 吲哚衍生物作为ras抑制剂及其应用
CN119431325A (zh) * 2024-10-31 2025-02-14 诚达药业股份有限公司 一种3-(1h-吡唑-1-基)氮杂环丁烷类化合物及其合成方法
WO2026124659A1 (zh) * 2024-12-13 2026-06-18 苏州泽璟生物制药股份有限公司 二羰基类抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317393A (en) 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses
DE102019122206B4 (de) 2019-08-19 2021-07-08 Webasto SE Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy

Also Published As

Publication number Publication date
TW202313631A (zh) 2023-04-01
US20240277796A1 (en) 2024-08-22
CN117715658A (zh) 2024-03-15
CN118557730A (zh) 2024-08-30
AU2022281343A1 (en) 2023-11-30
IL308771A (en) 2024-01-01
JP2024521774A (ja) 2024-06-04
WO2022251292A1 (en) 2022-12-01
CA3219533A1 (en) 2022-12-01
EP4346898A1 (en) 2024-04-10
KR20240026526A (ko) 2024-02-28

Similar Documents

Publication Publication Date Title
IL308195A (en) RAS inhibitors for cancer treatment
PH12021553000A1 (en) Multispecific proteins
ZA202003176B (en) Compounds useful as kinase inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CR20220243A (es) Inhibidores de ras
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2024003713A (es) Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3).
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
EA201791736A1 (ru) Комбинированная терапия для лечения рака
AU2018301696A8 (en) Heterocyclic inhibitors of ATR kinase
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2020006297A (es) Variantes de cd19.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof